|
US5811542A
(en)
*
|
1989-09-08 |
1998-09-22 |
Alpha-Beta Technology, Inc. |
Method for producing soluble glucans
|
|
US5622939A
(en)
*
|
1992-08-21 |
1997-04-22 |
Alpha-Beta Technology, Inc. |
Glucan preparation
|
|
EP0490995A1
(de)
*
|
1989-09-08 |
1992-06-24 |
Alpha Beta Technology |
Verfahren zur herstellung von wasserlöslichen glukanen
|
|
FR2655267B1
(fr)
*
|
1989-12-04 |
1992-04-03 |
Roussel Uclaf |
Nouveau derive sulfate du galactanne extrait de klebsiella, procede de preparation, application a titre de medicaments et compositions pharmaceutiques le renfermant.
|
|
JPH0665649B2
(ja)
*
|
1991-02-01 |
1994-08-24 |
台糖株式会社 |
甲殻類の生体防御能増強剤、感染症予防ワクチン及び飼料
|
|
FR2674755B1
(fr)
*
|
1991-04-05 |
1995-02-03 |
Thorel Jean Noel |
Nouvelles compositions medicamenteuses immunostimulatrices.
|
|
JP3522772B2
(ja)
*
|
1991-05-21 |
2004-04-26 |
台糖株式会社 |
ワクチンの免疫効果増強剤
|
|
ZA93216B
(en)
*
|
1992-01-17 |
1993-08-18 |
Solvay Animal Health Inc |
Vaccine containing acemannan as an adjuvant.
|
|
EP0640348A1
(de)
*
|
1993-07-26 |
1995-03-01 |
Akzo Nobel N.V. |
Adjuvansmischung auf Ölbasis und auf Wasserbasis
|
|
DK0788377T3
(da)
*
|
1993-07-28 |
2000-12-27 |
Diatide Inc |
Radiomærkede glucaner
|
|
US5919466A
(en)
*
|
1993-10-01 |
1999-07-06 |
Gerbu Biotechnik Gmbh |
Method for improving the yield of immunoantibodies in the vaccination of animals and humans
|
|
AUPM572294A0
(en)
*
|
1994-05-18 |
1994-06-09 |
Vaccine Technologies Pty. Ltd. |
Delivery vehicle for bioactive molecule
|
|
US5714163A
(en)
*
|
1994-06-27 |
1998-02-03 |
Nexstar Pharmaceuticals, Inc. |
Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
|
|
US5622940A
(en)
*
|
1994-07-14 |
1997-04-22 |
Alpha-Beta Technology |
Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
|
|
US5576015A
(en)
*
|
1995-03-02 |
1996-11-19 |
Donzis; Byron A. |
Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
|
|
AUPN166195A0
(en)
*
|
1995-03-13 |
1995-04-06 |
Norvet Research Pty Limited |
Process for glucan extraction
|
|
KR19990028383A
(ko)
*
|
1995-06-26 |
1999-04-15 |
지 더블유 페이스 |
신규한 보조제 조성물 및 이것을 함유한 백신 제제
|
|
US5785975A
(en)
*
|
1995-06-26 |
1998-07-28 |
Research Triangle Pharmaceuticals |
Adjuvant compositions and vaccine formulations comprising same
|
|
US20080286228A1
(en)
*
|
1995-10-20 |
2008-11-20 |
Tarantolo Stefano R |
Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
|
|
CA2232344C
(en)
*
|
1995-10-20 |
2005-04-05 |
University Of Nebraska Board Of Regents |
Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
|
|
US6084092A
(en)
*
|
1997-01-31 |
2000-07-04 |
The Collaborative Group, Ltd. |
β(1-3)-glucan diagnostic assays
|
|
US6110692A
(en)
*
|
1996-05-01 |
2000-08-29 |
The Collaborative Group, Ltd. |
Receptor for underivatized aqueous soluble β(1-3)-glucan
|
|
JPH10139670A
(ja)
*
|
1996-11-11 |
1998-05-26 |
Terukuni Yakida |
インターロイキン12誘導物質及び医薬組成物
|
|
US20060002949A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
|
US6797276B1
(en)
*
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
|
US6413715B2
(en)
|
1997-01-31 |
2002-07-02 |
The Collaborative Group |
β(1-3)-glucan diagnostic assays
|
|
US5786343A
(en)
*
|
1997-03-05 |
1998-07-28 |
Immudyne, Inc. |
Phagocytosis activator compositions and their use
|
|
DE19737481A1
(de)
*
|
1997-08-28 |
1999-03-04 |
Hoechst Ag |
Sphärische lineare Polysaccharide enthaltende Mikropartikel
|
|
JP2001518556A
(ja)
*
|
1997-10-03 |
2001-10-16 |
ガレニカ ファーマシューティカルズ, インコーポレイテッド |
イミン形成ポリサッカライド、その調製、ならびにアジュバントおよび免疫刺激剤としてのその使用
|
|
US6756361B1
(en)
*
|
1997-10-14 |
2004-06-29 |
Nabi |
Enterococcus antigens and vaccines
|
|
AU1786799A
(en)
*
|
1997-12-18 |
1999-07-05 |
Instituut Voor Agrotechnologisch Onderzoek (Ato-Dlo) |
Composition for the controlled release of active compounds
|
|
US6573245B1
(en)
|
1998-04-28 |
2003-06-03 |
Galenica Pharmaceuticals, Inc. |
Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
|
|
WO2000014547A1
(en)
*
|
1998-09-04 |
2000-03-16 |
Powderject Research Limited |
Immunodiagnostics using particle delivery methods
|
|
ES2321892T3
(es)
*
|
1998-09-14 |
2009-06-12 |
Nabi Biopharmaceuticals |
Composiciones de beta-glucanos e inmunoglobulinas especificas.
|
|
US7030101B2
(en)
|
1998-09-14 |
2006-04-18 |
Nabi Biopharmaceuticals |
Compositions of β-glucans and specific antibodies
|
|
US6369216B1
(en)
|
1998-09-25 |
2002-04-09 |
Biopolymer Engineering Pharmaceutical, Inc. |
Very high molecular weight β-glucans
|
|
AU6261999A
(en)
|
1998-09-25 |
2000-04-17 |
Collaborative Group, Ltd., The |
Very high molecular weight beta-glucans
|
|
US6541678B2
(en)
*
|
1999-09-27 |
2003-04-01 |
Brennen Medical, Inc. |
Immunostimulating coating for surgical devices
|
|
US20020009463A1
(en)
*
|
2000-02-23 |
2002-01-24 |
Jan Raa |
Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
|
|
CA2434938C
(en)
*
|
2001-01-16 |
2012-02-28 |
Sloan-Kettering Institute For Cancer Research |
Compositions of glucan and a monoclonal antibody which exhibit an enhancement of the anti tumor activity of the antibody
|
|
US7906492B2
(en)
*
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
US7507724B2
(en)
*
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
EP1372708B1
(de)
|
2001-02-13 |
2008-06-18 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY |
Impstoffe zur transkutanen immunisierung gegen reisediarrhö
|
|
TWI300714B
(en)
*
|
2001-04-27 |
2008-09-11 |
Ajinomoto Kk |
Immunopotentiators
|
|
NO20014256D0
(no)
*
|
2001-09-03 |
2001-09-03 |
Bjoern Kristiansen |
Fremstilling av immunstimulerende forbindelse
|
|
US7786094B2
(en)
*
|
2001-10-09 |
2010-08-31 |
Biopolymer Engineering, Inc. |
Use of beta-glucans against biological warfare weapons and pathogens including anthrax
|
|
AU2002347165B2
(en)
|
2001-12-11 |
2008-05-29 |
Ceapro Inc. |
Cereal beta glucan compositions, methods of preparation and uses thereof
|
|
WO2004012657A2
(en)
*
|
2002-08-01 |
2004-02-12 |
Immusonic, Inc. |
Beta-glucan containing composites, methods for manufacturing and for using such composites
|
|
WO2004014320A2
(en)
*
|
2002-08-13 |
2004-02-19 |
Biopolymer Engineering, Inc. |
Methods of using beta glucan as a radioprotective agent
|
|
CA2496508C
(en)
|
2002-09-04 |
2014-04-22 |
University Of Louisville Research Foundation, Inc. |
Cancer therapy using beta glucan and antibodies
|
|
US20060165700A1
(en)
*
|
2002-09-04 |
2006-07-27 |
Ostroff Gary R |
Cancer therapy using whole glucan particles and antibodies
|
|
US20050281875A1
(en)
*
|
2003-12-17 |
2005-12-22 |
Sovereign Pharmaceuticals, Ltd. |
Promethazine containing dosage form
|
|
US20060029664A1
(en)
*
|
2004-08-04 |
2006-02-09 |
Sovereign Pharmaceuticals, Ltd. |
Dosage form containing carbetapentane and another drug
|
|
US20050232986A1
(en)
*
|
2003-12-17 |
2005-10-20 |
David Brown |
Dosage form containing promethazine and another drug
|
|
US9492541B2
(en)
*
|
2004-09-14 |
2016-11-15 |
Sovereign Pharmaceuticals, Llc |
Phenylepherine containing dosage form
|
|
US20050266032A1
(en)
*
|
2003-12-17 |
2005-12-01 |
Sovereign Pharmaceuticals, Ltd. |
Dosage form containing multiple drugs
|
|
US20050232987A1
(en)
*
|
2004-03-12 |
2005-10-20 |
Viswanathan Srinivasan |
Dosage form containing a morphine derivative and another drug
|
|
ES2899590T3
(es)
|
2004-01-23 |
2022-03-14 |
Eden Research Plc |
Métodos de eliminación de nematodos que comprenden la aplicación de un componente terpénico
|
|
US20050208145A1
(en)
*
|
2004-03-19 |
2005-09-22 |
Thava Vasanthan |
Grain fiber compositions and methods of use
|
|
US20050220846A1
(en)
|
2004-04-05 |
2005-10-06 |
Puntenney Steven B |
Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
|
|
NZ551644A
(en)
|
2004-05-20 |
2010-06-25 |
Eden Research Plc |
Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them
|
|
US7740861B2
(en)
*
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
|
US7514085B2
(en)
|
2004-07-16 |
2009-04-07 |
Medimush A/S |
Immune modulating compounds from fungi
|
|
US9592197B2
(en)
*
|
2004-12-16 |
2017-03-14 |
Sovereign Pharmaceuticals, Llc |
Dosage form containing diphenhydramine and another drug
|
|
US20070003622A1
(en)
*
|
2004-12-16 |
2007-01-04 |
Sovereign Pharmaceuticals, Ltd. |
Diphenhydramine containing dosage form
|
|
AU2005284727A1
(en)
*
|
2004-09-17 |
2006-03-23 |
University Of Massachusetts |
Compositions and their uses for lysosomal enzyme deficiencies
|
|
MX2007013725A
(es)
|
2005-05-05 |
2008-04-09 |
Sensient Flavors Inc |
Produccion de beta-glucanos y mananos.
|
|
US9072776B2
(en)
|
2005-06-15 |
2015-07-07 |
Glycanova As |
Anti-cancer combination treatment and kit-of-parts
|
|
US20090005340A1
(en)
*
|
2005-06-15 |
2009-01-01 |
Medimush A/S |
Bioactive Agents Produced By Submerged Cultivation of a Basidiomycete Cell
|
|
AU2006306228A1
(en)
*
|
2005-10-24 |
2007-05-03 |
University Of Massachusetts |
Compositions and their uses for gene therapy of bone conditions
|
|
WO2007063268A1
(en)
|
2005-11-30 |
2007-06-07 |
Eden Research Plc |
Compositions and methods comprising terpenes or terpene mixtures selected from thymol, eugenol, geraniol, citral, and l-carvone
|
|
BRPI0619219B8
(pt)
*
|
2005-11-30 |
2021-11-16 |
Univ Cornell |
Método para matar ácaros, método para tratar ou impedir a infestação por um ácaro em uma planta e uso de uma composição
|
|
US20090053221A1
(en)
*
|
2006-01-17 |
2009-02-26 |
Cheung Nai-Kong V |
Immune response enhancing glucan
|
|
US8323644B2
(en)
|
2006-01-17 |
2012-12-04 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
|
US20080044438A1
(en)
*
|
2006-03-17 |
2008-02-21 |
Ostroff Gary R |
Yeast Cell Particles As Oral Delivery Vehicles For Antigens
|
|
US9610303B2
(en)
*
|
2006-06-15 |
2017-04-04 |
Biothera, Inc. |
Glucan preparations
|
|
WO2008027581A1
(en)
*
|
2006-09-01 |
2008-03-06 |
University Of Louisville |
Mcrp antagonists and their uses
|
|
WO2008027580A2
(en)
*
|
2006-09-01 |
2008-03-06 |
University Of Louisville |
PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
|
|
US20090022799A1
(en)
*
|
2006-10-06 |
2009-01-22 |
Shikha Pramanik Barman |
Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use
|
|
WO2008057501A2
(en)
*
|
2006-11-06 |
2008-05-15 |
Whitehead Institute |
Immunomodulating compositions and methods of use thereof
|
|
US9457047B2
(en)
|
2006-11-06 |
2016-10-04 |
Whitehead Institute |
Immunomodulating compositions and methods of use thereof
|
|
US8389485B2
(en)
*
|
2007-10-29 |
2013-03-05 |
University Of Massachusetts |
Encapsulated nanoparticles for nucleic acid delivery
|
|
WO2009114153A1
(en)
*
|
2008-03-12 |
2009-09-17 |
Nektar Therapeutics |
Oligomer-foscarnet conjugates
|
|
WO2009114151A1
(en)
|
2008-03-12 |
2009-09-17 |
Nektar Therapeutics |
Oligomer-amino acid and olgomer-atazanavir conjugates
|
|
WO2009120358A1
(en)
*
|
2008-03-27 |
2009-10-01 |
Nektar Therapeutics |
Oligomer-nitrogenous base conjugates
|
|
EP2105145A1
(de)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
|
|
EP2265290B1
(de)
*
|
2008-04-11 |
2014-06-04 |
Nektar Therapeutics |
Poly(alkylen oxid)-aryloxy-substituierte propanaminkonjugate
|
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
|
WO2010014258A2
(en)
*
|
2008-08-01 |
2010-02-04 |
Nektar Therapeutics Al, Corporation |
Conjugates having a releasable linkage
|
|
KR101671537B1
(ko)
|
2008-08-11 |
2016-11-01 |
넥타르 테라퓨틱스 |
다분지형 중합체 알카노에이트 컨쥬게이트
|
|
US9433684B2
(en)
|
2008-08-19 |
2016-09-06 |
Nektar Therapeutics |
Conjugates of small-interfering nucleic acids
|
|
EP2690175B1
(de)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
|
|
EP2350118B1
(de)
*
|
2008-09-19 |
2016-03-30 |
Nektar Therapeutics |
Kohlenhydratbasisierte polymere zur wirkstoffabgabe und konjugate davon
|
|
US20110171162A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of thymosin alpha 1 peptides
|
|
WO2010033204A2
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of c-peptides
|
|
US20110206633A1
(en)
*
|
2008-09-19 |
2011-08-25 |
Nektar Therapectics |
Polymer conjugates of cd-np peptides
|
|
AU2009292651A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of AOD-like peptides
|
|
US20110171166A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of osteocalcin peptides
|
|
WO2010033223A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Nektar Therapeutics |
Polymer conjugates of opioid growth factor peptides
|
|
EP2340047A1
(de)
*
|
2008-09-19 |
2011-07-06 |
Nektar Therapeutics |
Polymerkonjugate von kiss1-peptiden
|
|
US20110165113A1
(en)
*
|
2008-09-19 |
2011-07-07 |
Nektar Therapeutics |
Polymer conjugates of v681-like peptides
|
|
US20110171164A1
(en)
*
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
|
US9192681B2
(en)
|
2009-02-24 |
2015-11-24 |
Nektar Therapeutics |
Oligomer-amino acid conjugates
|
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
|
US8530492B2
(en)
|
2009-04-17 |
2013-09-10 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
|
WO2010120388A1
(en)
|
2009-04-17 |
2010-10-21 |
Nektar Therapeutics |
Oligomer-protein tyrosine kinase inhibitor conjugates
|
|
CA2760706C
(en)
|
2009-05-05 |
2019-08-06 |
Alnylam Pharmaceuticals, Inc. |
Methods of delivering oligonucleotides to immune cells
|
|
WO2010132693A2
(en)
|
2009-05-13 |
2010-11-18 |
Nektar Therapeutics |
Oligomer-containing pyrrolidine compounds
|
|
WO2010132691A1
(en)
|
2009-05-13 |
2010-11-18 |
Nektar Therapeutics |
Oligomer-containing substituted aromatic triazine compounds
|
|
WO2011035065A1
(en)
|
2009-09-17 |
2011-03-24 |
Nektar Therapeutics |
Monoconjugated chitosans as delivery agents for small interfering nucleic acids
|
|
WO2011061144A2
(en)
|
2009-11-20 |
2011-05-26 |
Basf Se |
The present invention relates to the use of beta-(1, 3)- beta-(1, 4) glucan with an average molecular weight of from 5.000 to 150.000 da for the increase of synthesis of collagen
|
|
CZ302789B6
(cs)
*
|
2009-11-25 |
2011-11-09 |
Zentiva, K. S. |
Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
|
|
MX339050B
(es)
|
2009-12-18 |
2016-05-09 |
Novartis Ag |
Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
|
|
WO2011103559A1
(en)
|
2010-02-22 |
2011-08-25 |
Nektar Therapeutics |
Oligomer modified diaromatic substituted compounds
|
|
CA2794189C
(en)
|
2010-03-24 |
2022-01-11 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
|
EP3578657B1
(de)
|
2010-04-06 |
2024-03-20 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der cd274/pd-l1-genexpression
|
|
CA3098080A1
(en)
|
2010-04-23 |
2011-10-27 |
Arrowhead Research Corporation |
Organic compositions to treat beta-enac-related diseases
|
|
US20110293784A1
(en)
|
2010-05-28 |
2011-12-01 |
Anja Wittke |
Milk-based nutritional compositions
|
|
EP3456827A3
(de)
|
2010-06-02 |
2019-05-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von leberfibrose
|
|
EP2603450B1
(de)
|
2010-08-14 |
2016-11-02 |
University of Massachusetts |
Wandpartikel aus hefezellen für rezeptorengerichtete nanopartikelfreisetzung
|
|
EP2627639B1
(de)
|
2010-10-15 |
2021-12-22 |
Nektar Therapeutics |
N-optional substituierte aryl-2-oligomer-3-alkoxypropionamides
|
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
|
US9540330B2
(en)
|
2010-12-15 |
2017-01-10 |
Nektar Therapeutics |
Oligomer-containing hydantoin compounds
|
|
WO2012083153A1
(en)
|
2010-12-16 |
2012-06-21 |
Nektar Therapeutics |
Oligomer-containing apremilast moiety compounds
|
|
WO2012088433A1
(en)
|
2010-12-22 |
2012-06-28 |
Nektar Therapeutics |
Deuterated and/or fluorinated taxane derivatives
|
|
US10894087B2
(en)
|
2010-12-22 |
2021-01-19 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
|
|
US20130331443A1
(en)
|
2010-12-22 |
2013-12-12 |
Nektar Therapeutics |
Multi-arm polymeric prodrug conjugates of taxane-based compounds
|
|
WO2012088506A1
(en)
|
2010-12-23 |
2012-06-28 |
Nektar Therapeutics |
Polymer-semaxanib moiety conjugates
|
|
US9827326B2
(en)
|
2010-12-23 |
2017-11-28 |
Nektar Therapeutics |
Polymer-sunitinib conjugates
|
|
US10220020B2
(en)
|
2010-12-23 |
2019-03-05 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
|
KR102104401B1
(ko)
|
2011-03-29 |
2020-04-27 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
CA2839573A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
|
CA2839896A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
US20140235693A1
(en)
|
2011-06-23 |
2014-08-21 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
JP2014526887A
(ja)
|
2011-08-01 |
2014-10-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
造血幹細胞移植の成功率を改善する方法
|
|
US20160032284A1
(en)
|
2011-09-02 |
2016-02-04 |
Arrowhead Research Corportation |
Organic compositions to treat hsf1-related diseases
|
|
BR112014016870A2
(pt)
|
2012-01-09 |
2017-06-27 |
Huesken Dieter |
composições orgânicas para tratar doenças relacionadas com beta-catenina
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
RU2666953C2
(ru)
*
|
2012-07-05 |
2018-09-13 |
Нутрамакс Лабораториз, Инк. |
Композиции, содержащие сульфорафан или предшественник сульфорафана и экстракт или порошок молочного чертополоха
|
|
US20140065173A1
(en)
|
2012-09-06 |
2014-03-06 |
Orbis Health Solutions Llc |
Tumor lysate loaded particles
|
|
JP6265998B2
(ja)
|
2012-09-17 |
2018-01-24 |
ネクター セラピューティクス |
オリゴマー含有ベンズアミド系化合物
|
|
GB201220940D0
(en)
|
2012-11-21 |
2013-01-02 |
Eden Research Plc |
Method P
|
|
WO2014093454A1
(en)
|
2012-12-12 |
2014-06-19 |
Orbis Health Solutions, Llc |
Compositions and methods for tissue regeneration
|
|
US20150366890A1
(en)
|
2013-02-25 |
2015-12-24 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
|
PT2970974T
(pt)
|
2013-03-14 |
2017-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de componente do complemento c5 e métodos para a sua utilização
|
|
WO2014182661A2
(en)
|
2013-05-06 |
2014-11-13 |
Alnylam Pharmaceuticals, Inc |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
|
MX385871B
(es)
|
2013-10-02 |
2025-03-18 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
|
WO2015051318A1
(en)
|
2013-10-04 |
2015-04-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
|
KR102343005B1
(ko)
*
|
2013-10-09 |
2021-12-24 |
도레이 카부시키가이샤 |
면역 부활화제
|
|
AP2016009288A0
(en)
|
2013-11-21 |
2016-06-30 |
Eden Research Plc |
Pesticidal composition
|
|
WO2015085113A1
(en)
|
2013-12-04 |
2015-06-11 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of wound healing utilizing chemically modified oligonucleotides
|
|
US10189859B2
(en)
|
2013-12-21 |
2019-01-29 |
Nektar Therapeutics |
Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
|
|
EP3105331B1
(de)
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
PT3110437T
(pt)
|
2014-02-12 |
2018-01-16 |
Omnigen Res Llc |
Composição e método para promover a redução do stress térmico em animais
|
|
EP3113759B1
(de)
|
2014-03-05 |
2021-05-12 |
Orbis Health Solutions LLC |
Impfstoffabgabesysteme mit hefezellwandpartikeln
|
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
|
CA2947619A1
(en)
|
2014-05-01 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
|
JP6893594B2
(ja)
|
2014-07-10 |
2021-06-23 |
ハイバーセル,インク. |
腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
|
|
EP3188799B1
(de)
|
2014-09-05 |
2022-07-06 |
Phio Pharmaceuticals Corp. |
Verfahren zur behandlung von alterung und hauterkrankungen mit auf tyr oder mmp1 gerichteten nukleinsäuren
|
|
WO2016038550A1
(en)
|
2014-09-11 |
2016-03-17 |
Novartis Ag |
Inhibition of prmt5 to treat mtap-deficiency-related diseases
|
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
|
EP3904519A1
(de)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
|
JP6887378B2
(ja)
|
2014-11-06 |
2021-06-16 |
バイオセラ,インク. |
腫瘍内微小環境に影響を与えるベータ−グルカン方法と組成物
|
|
EP3227446A1
(de)
|
2014-12-01 |
2017-10-11 |
Novartis AG |
Zusammensetzungen und verfahren zur diagnose und behandlung von prostatakrebs
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
US20170369872A1
(en)
|
2014-12-18 |
2017-12-28 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
CN107787367B
(zh)
|
2015-04-06 |
2021-10-26 |
里兰斯坦福初级大学理事会 |
用于crispr/cas介导的基因调控的化学修饰的引导rna
|
|
EP3302525A2
(de)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Verfahren und zusammensetzungen zur diagnose, behandlung und überwachung der behandlung von shank3-mangelbedingten erkrankungen
|
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
US11001845B2
(en)
|
2015-07-06 |
2021-05-11 |
Phio Pharmaceuticals Corp. |
Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
|
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
|
US10526590B2
(en)
|
2015-08-31 |
2020-01-07 |
Agilent Technologies, Inc. |
Compounds and methods for CRISPR/Cas-based genome editing by homologous recombination
|
|
US10889813B2
(en)
|
2015-09-02 |
2021-01-12 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
|
|
CN120937999A
(zh)
|
2015-09-09 |
2025-11-14 |
奥姆尼根研究有限责任公司 |
颗粒组合物在制备用于施用于水生动物的组合物和/或组合中的用途
|
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
|
IL308717A
(en)
|
2015-12-07 |
2024-01-01 |
Genzyme Corp |
Methods and compositions for treating a serpinc1-associated disorder
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
EP3469083A1
(de)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
|
|
CA3031097A1
(en)
|
2016-07-18 |
2018-01-25 |
Tissuegen, Inc. |
Methods and compositions for maintaining the conformation and structural integrity of biomolecules
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
WO2018130395A1
(en)
*
|
2017-01-10 |
2018-07-19 |
Unilever Plc |
Biofilm targeting microcapsule carrying a non-volatile functional material
|
|
AU2018207283C1
(en)
|
2017-01-10 |
2024-05-02 |
Nektar Therapeutics |
Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
|
|
WO2018156888A1
(en)
|
2017-02-24 |
2018-08-30 |
Biothera Pharmaceuticals, Inc. |
Beta glucan immunopharmacodynamics
|
|
JP7167059B2
(ja)
|
2017-04-19 |
2022-11-08 |
フィオ ファーマシューティカルズ コーポレーション |
核酸化合物の局所送達
|
|
EP3628010A4
(de)
|
2017-05-02 |
2021-02-17 |
Nektar Therapeutics |
Immuntherapeutisches tumorbehandlungsverfahren
|
|
JP2020530442A
(ja)
|
2017-07-10 |
2020-10-22 |
ジェンザイム・コーポレーション |
血友病を有する対象の出血事象を処置するための方法および組成物
|
|
CA3069868A1
(en)
|
2017-07-13 |
2019-01-17 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
|
EP4085919A3
(de)
|
2017-07-21 |
2023-02-08 |
Novartis AG |
Zusammensetzungen und verfahren zur behandlung von krebs
|
|
US12030940B2
(en)
|
2017-08-17 |
2024-07-09 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
US20200339987A1
(en)
|
2017-11-09 |
2020-10-29 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining expression of the lect2 gene
|
|
WO2019094962A2
(en)
*
|
2017-11-13 |
2019-05-16 |
The Regents Of The University Of California |
Antimicrobial particles and sanitization methods
|
|
US10835581B2
(en)
|
2017-11-28 |
2020-11-17 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Method of treating insulin resistance
|
|
US11179412B2
(en)
|
2017-12-04 |
2021-11-23 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Methods of treating conditions involving elevated inflammatory response
|
|
GB201800417D0
(en)
*
|
2018-01-11 |
2018-02-28 |
Whelan Adam Owen |
Immunogenic agent and associated compositions, uses and methods
|
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
|
WO2019165212A1
(en)
|
2018-02-22 |
2019-08-29 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
TARGETING CANCER-ASSOCIATED LONG NON-CODING RNAs
|
|
CN110237249A
(zh)
*
|
2018-03-09 |
2019-09-17 |
南开大学 |
特异靶向树突状细胞的新型铝佐剂及在疫苗制备上的应用
|
|
WO2019178443A1
(en)
*
|
2018-03-16 |
2019-09-19 |
University Of Massachusetts |
Yeast cell wall particle encapsulation of biodegradable pro-payloads
|
|
US20210123016A1
(en)
|
2018-05-02 |
2021-04-29 |
Novartis Ag |
Regulators of human pluripotent stem cells and uses thereof
|
|
AR115960A1
(es)
|
2018-08-16 |
2021-03-17 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión del gen lect2
|
|
JP2022500003A
(ja)
|
2018-09-18 |
2022-01-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
|
PT4285929T
(pt)
|
2018-12-20 |
2026-01-02 |
Humabs Biomed Sa |
Terapêutica de combinação contra o vhb
|
|
NO346800B1
(en)
|
2019-06-28 |
2023-01-16 |
Ederagen As |
Deconstructed soil composition
|
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
US12503699B2
(en)
|
2019-10-04 |
2025-12-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing UGT1a1 gene expression
|
|
TW202130809A
(zh)
|
2019-10-29 |
2021-08-16 |
美商愛羅海德製藥公司 |
用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
|
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
CA3160657A1
(en)
|
2019-11-08 |
2021-05-14 |
Phio Pharmaceuticals Corp. |
Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
PH12022552080A1
(en)
|
2020-02-10 |
2024-02-12 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing vegf-a expression
|
|
US20230092615A1
(en)
|
2020-02-21 |
2023-03-23 |
Mitotherapeutix Llc |
Compositions and methods for inhibiting expressing of methylation-controlled j-protein (mcj)
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
IL297121A
(en)
|
2020-04-06 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing myoc expression
|
|
AU2021251754A1
(en)
|
2020-04-07 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing SCN9A expression
|
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
CN116075592A
(zh)
|
2020-06-09 |
2023-05-05 |
阿尔尼拉姆医药品有限公司 |
用于沉默gpam(线粒体甘油-3-磷酸酰基转移酶1)表达的sirna组合物和方法
|
|
BR112022026316A2
(pt)
|
2020-06-24 |
2023-03-07 |
Vir Biotechnology Inc |
Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
|
|
JPWO2022045371A1
(de)
*
|
2020-08-31 |
2022-03-03 |
|
|
|
MX2023014008A
(es)
|
2021-05-27 |
2023-12-11 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion de anhidrasa carbonica 2.
|
|
TW202325311A
(zh)
|
2021-08-31 |
2023-07-01 |
美商艾拉倫製藥公司 |
誘導細胞死亡之DFFA樣效應子B (CIDEB) iRNA組合物及其使用方法
|
|
WO2023039586A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
|
KR20240103025A9
(ko)
|
2021-11-16 |
2025-12-10 |
상하이 아르고 바이오파마슈티칼 씨오., 엘티디. |
안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
|
|
KR20240111795A
(ko)
|
2021-11-29 |
2024-07-17 |
상하이 아르고 바이오파마슈티칼 씨오., 엘티디. |
B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법
|
|
TW202345865A
(zh)
|
2022-01-24 |
2023-12-01 |
大陸商上海舶望製藥有限公司 |
抑制LPA(Apo(a))蛋白表達的組合物和方法
|
|
CN115317601B
(zh)
*
|
2022-04-13 |
2026-02-27 |
暨南大学 |
一种新冠疫苗载体及其应用
|
|
CN119907856A
(zh)
|
2022-09-15 |
2025-04-29 |
阿尔尼拉姆医药品有限公司 |
第13型17β-羟基类固醇脱氢酶(HSD17B13)iRNA组合物及其使用方法
|
|
IL322261A
(en)
|
2023-02-09 |
2025-09-01 |
Alnylam Pharmaceuticals Inc |
Reverser molecules and methods of using them
|
|
TW202516009A
(zh)
|
2023-10-10 |
2025-04-16 |
大陸商上海舶望製藥有限公司 |
抑制澱粉樣前體蛋白(app)表達的組合物和方法
|
|
WO2025128632A1
(en)
|
2023-12-12 |
2025-06-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating ketohexokinase (khk)-associated diseases
|
|
AU2024400950A1
(en)
|
2023-12-12 |
2026-06-11 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating transthyretin (ttr)- associated diseases
|